The multifaceted oncogene c-Myc plays important roles in the development and progression of human cancer. Recent in vitro and in vivo studies have shown that the p19Arf-Mdm2-p53 and the ribosomal protein (RP)-Mdm2-p53 pathways are both essential in preventing oncogenic c-Myc-induced tumorigenesis. Disruption of each pathway individually by p19Arf deletion or by Mdm2 C305F mutation, which disrupts RP-Mdm2 binding, accelerates Eμ-myc transgene-induced pre-B/B-cell lymphoma in mice at seemingly similar paces with median survival around 10 and 11 weeks, respectively, compared to 20 weeks for Eμ-myc transgenic mice. Because p19Arf can inhibit ribosomal biogenesis through its interaction with nucleophosmin (NPM/B23), RNA helicase DDX5 and RNA polymerase I transcription termination factor (TTF-I), it has been speculated that the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 pathways might be a single p19Arf-RP-Mdm2-p53 pathway, in which p19Arf activates p53 by inhibiting RP biosynthesis; thus, p19Arf deletion or Mdm2 C305F mutation would result in similar consequences. Here, we generated mice with concurrent p19Arf deletion and Mdm2 C305F mutation and investigated the compound mice for tumorigenesis in the absence and the presence of oncogenic c-Myc overexpression. In the absence of Eμ-myc transgene, the Mdm2 C305F mutation did not elicit spontaneous tumors in mice, nor did it accelerate spontaneous tumors in mice with p19Arf deletion. In the presence of Eμ-myc transgene, however, Mdm2 C305F mutation significantly accelerated p19Arf deletion-induced lymphomagenesis and promoted rapid metastasis. We found that when p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways are independently disrupted, oncogenic c-Myc-induced p53 stabilization and activation is only partially attenuated. When both pathways are concurrently disrupted, however, c-Myc-induced p53 stabilization and activation are essentially obliterated. Thus, the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 are non-redundant pathways possessing similar capabilities to activate p53 upon c-Myc overexpression.
INTRODUCTION
The Myc protein (c-Myc) is a helix-loop-helix leucine zipper transcriptional regulator, which forms specific DNA-binding heterodimers with the Max protein to control a variety of normal cellular functions. 1 In addition, c-Myc facilitates the recruitment of Pol I (DNA polymerase I) to ribosomal DNA promoters, 2 promotes the transcription of ribosomal proteins (RPs) by activating Pol II 3 and activates Pol III-mediated transcription of 5S ribosomal RNA and transfer RNA. 4 In addition, c-Myc is known to regulate ribosomal biogenesis through the transactivation of genes involved in ribosomal biogenesis, including RPs themselves. 5 Increased c-Myc expression is frequently observed in human cancers and it can confer a growth advantage to cells by providing constitutive proliferative signals. 6 However, c-Myc overexpression may also initiate an endogenous apoptotic program, 7 and through this function trigger a potent tumor surveillance response that effectively opposes hyperproliferation by killing those cells in which c-Myc levels exceed a safe threshold. 8 The p53 transcription factor is a critical tumor suppressor, and when activated it triggers cell cycle arrest, differentiation, apoptosis and senescence. The TP53 gene is mutated in~50% of all human tumors and is often referred to as the 'guardian' of the genome. 9,10 p53 is primarily regulated by the E3 ubiquitin ligase murine double minute 2 (Mdm2), which binds to p53 to both block its transactivation domain and to promote its ubiquitination and degradation. However, p53 enhances Mdm2 transcription, thus forming an autoregulatory feedback loop. 11 The tumor suppressor p19 alternative reading frame (p19Arf, p14Arf in human) is transcribed from an alternative reading frame of the INK4a/ARF locus. p19Arf physically binds to Mdm2, inhibiting its E3 ligase activity, thereby stabilizing and activating p53, which constitutes a p19Arf-Mdm2-p53 signaling pathway. 12 Oncogenic c-Myc driven tumors receive a selective advantage from inactivation of the p19Arf-Mdm2-p53 pathway, diminishing its protective checkpoint function and accelerating normal cell progression to malignancy; this accelerated progression to malignancy is observed in Eμ-myc;p19Arf −/− transgenic mice, a model for Burkitt's lymphoma, which die of lymphoma within a few weeks of birth. 13 Previous evidence has demonstrated that several RPs such as RPL5, RPL11 and RPL23 interact with Mdm2 to inhibit its E3 ligase function, thereby stabilizing and activating p53, suggesting an RP-Mdm2-p53 pathway. 14 In vivo studies have established the physiological significance of the RP-Mdm2 interaction in responding to ribosomal stress to activate p53, providing evidence for a p53 checkpoint mediated by the RP-Mdm2 interaction, which is capable of monitoring the integrity of ribosome biogenesis. 15 Furthermore, use of the Eμ-myc transgenic mouse model, which constitutively expresses c-Myc in the B-cell lineage and develops B-cell lymphoma at an early age, 16 we have demonstrated that the RP-Mdm2-p53 pathway, similar to the p19Arf-Mdm2-p53 pathway, plays a critical role in preventing oncogenic c-Myc-induced lymphomagenesis. 15 Previous studies have shown that p19Arf can disturb ribosomal biogenesis by interacting with nucleophosmin (NPM/B23) and inhibiting pre-ribosomal RNA processing. 17, 18 More recently, it has been shown that p19Arf inhibits the function of RNA polymerase I transcription termination factor 19 and DDX5 RNA helicase 20 by preventing their nucleolar localization, thereby inhibiting ribosomal biosynthesis. These studies raise an interesting question as to whether the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 pathways might function in a linear manner as a p19Arf-RP-Mdm2-p53 pathway, where p19Arf additionally activates p53 by inhibiting RP biosynthesis. As such, p19Arf deletion or Mdm2 C305F mutation, which disrupts RP-Mdm2 binding, would result in similar consequences in the context of c-Myc overexpression. To gain insight into the interrelationship and possible cooperative mechanisms between p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways, we studied tumorigenesis in mice with disruption of each pathway individually and in combination.
RESULTS
Mdm2 C305F mutation does not accelerate p19Arf deletion caused spontaneous tumor development Previous studies have shown that mice with homozygous deletion of p19Arf (p19Arf −/− ) are predisposed to spontaneous tumor development, 21 whereas mice with homozygous mutation of Mdm2 C305F (henceforth referred to as Mdm2 m/m ), which prevents Mdm2 binding to RPL5 and RPL11, 22 do not develop spontaneous tumors. 15 Because p19Arf interacts with and inhibits NPM/B23, 17, 18 RNA polymerase I transcription termination factor 19 and DDX5. 20 As these factors are all involved in ribosomal biosynthesis we speculated that the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 pathways might be functionally interconnected. We crossed p19Arf −/− and Mdm2 m/m mice to generate double-heterozygous Mdm2 +/m ;p19Arf +/ − mice and then intercrossed the Mdm2 +/m ; p19Arf +/ − mice to generate Mdm2 m/m ;p19Arf −/− compound mice. Of the 186 pups born from intercross of the double-heterozygotes, a predicted Mendelian inheritance was observed ( Figure 1a , shown are only three genotypes for simplicity), indicating that concurrent disruption of p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways does not affect embryogenesis and early development.
A survival study was carried out to examine the effect of concurrent p19Arf deletion and Mdm2 C305F mutation on spontaneous tumor formation and lifespan in the mice. Consistent with previous studies, mice heterozygous for Mdm2 C305F mutation (Mdm2 +/m ) and p19Arf deletion (p19Arf +/ − ) did not show any pathological or physiological changes. In addition, we did not observe any phenotypic changes in double-heterozygous Mdm2 +/m ; p19Arf +/ − mice (data not shown). Consistent with previous reports, 21 mice with homozygous deletion of p19Arf were predisposed to tumors, mostly lymphomas, and died shortly after the development of disease, resulting in a notably shorter lifespan compared to wild-type (WT) mice ( Figure 1b ). However, mice with homozygous Mdm2 C305F mutation did not show observable differences in spontaneous tumor formation and lifespan from the WT littermates. Interestingly, double-homozygous compound mice (Mdm2 m/m ;p19Arf −/− ) did not show accelerated spontaneous tumor formation compared to mice with only p19Arf deletion, instead they displayed slightly decelerated tumor formation ( Figure 1b ; log-rank test P = 0.06); the reasons for the deceleration remain unclear. We have noticed that the mean latency for survival of the p19Arf −/− mice in our experiment is 16 months, significantly longer than the previous report of~10 months. 21 One likely reason for the difference is that our mice are in 499% pure C57BL6 background as compared to a mixed 129svj/C57BL6 background in the previous study. It has been reported that C57BL6 mice are more resistant to spontaneous tumor formation than 129svj mice, 23, 24 and C57BL6 mice are more efficient in total leukocyte recruitment than 129svj mice, 25 a function important in preventing lymphomagenesis. 26 Concurrent disruption of the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 pathways further accelerates oncogenic c-Myc-induced lymphomagenesis To further investigate the consequence of disruption of the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 pathways on tumorigenesis, we generated Eμ-myc transgenic mice on Mdm2 m/m and p19Arf −/− background individually and in combination, and compared their tumor-free survival time. Eμ-myc;WT mice died of pre-B/B-cell lymphoma with a mortality curve consistent with previous studies (Figure 2 ). 13, 16 The median survival for Eμ-myc; p19Arf +/ − mice was 15.6 weeks, significantly shorter than Eμ-myc; WT mice (Figure 2a , P = 0.003), whereas the median survival for Eμ-myc;Mdm2 +/m mice was not significantly different from that of Eμ-myc;WT mice ( Figure 2b , P = 0.5). In contrast, homozygous Eμ-myc;p19Arf −/− and Eμ-myc;Mdm2 m/m mice developed aggressive, To determine if the RP-Mdm2-p53 and p19Arf-Mdm2-p53 represent two parallel pathways or a single linear p19Arf-RP-Mdm2-p53 pathway against Eμ-myc transgene-induced lymphomas, we generated Eμ-myc;Mdm2 m/m ;p19Arf −/− compound mice and evaluated the impact of the double mutation on mouse survival. Remarkably, Eμ-myc;Mdm2 m/m ;p19Arf −/− mice demonstrated a median survival of 7.6 weeks, evidently shorter than the lifespan observed in either Eμ-myc;Mdm2 m/m or Eμ-myc;p19Arf −/− mice ( Figure 2c ). These data indicate that the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 likely represent two independent signaling pathways possessing non-overlapping tumor suppression functions. We noticed that the mean survival of Eμ-myc;p19Arf −/− mice is significantly shorter than that of Eμ-myc;Mdm2 m/m mice (10.1 vs 11.6 weeks; Figure 2c , P = 0.0001). This indicates that in addition to directly inhibiting Mdm2 and activating p53, p19Arf may also partially exert its function through the RP-Mdm2-p53 pathway by inhibiting ribosomal biogenesis. 17, 18 No significant difference in body weight gain was observed among the genotypes in the early stages of the mouse lifespan ( Figure 2d ). In later stages, however, the Eμ-myc;p19Arf −/− mice grow larger, and the Eμ-myc;Mdm2 m/m mice grow smaller than the Eμ-myc;WT control mice. The reason for this discrepancy is unclear. In the final stages of their life, the mice began to lose weight from cancerous cachexia, indicating that these Eμ-myc transgenic mice die of cachexia due to malignant tumor development.
Mdm2 m/m ;p19Arf −/− mice demonstrate accelerated c-Myc-induced tumorigenesis and metastasis Splenomegaly is a common result of infiltration of lymphomas. Eμmyc transgenic mice typically present a massive enlargement of the spleen. 27 We measured the length of the spleens from mice at 9 weeks of age. As shown in Figure 3a , Eμ-myc;WT mice had an average spleen length of 1.6 cm, as compared to 1.1 cm spleen length in WT, non-transgenic mice. Both homozygous Mdm2 C305F mutation and p19Arf deletion accelerated splenomegaly, with average spleen size increased in Eμ-myc;Mdm2 m/m and Eμ-myc; p19Arf −/− transgenic mice to 2.4 and 2.5 cm, respectively. Compound mice harboring both Mdm2 C305F mutation and p19Arf deletion demonstrated further accelerated splenomegaly, and the average spleen length of Eμ-myc;Mdm2 m/m ;p19Arf −/− mice was 3.8 cm at 9 weeks of age.
We next examined the invasive nature of Eμ-myc-induced lymphomas in the spleen, liver and kidney tissues isolated from 9week-old mice. Spleen metastasis occurred earlier than other organs, and the structure of the spleens in mice harboring Eμ-myc transgene was already destroyed at this age. As shown in Figure 3b , expression of the Eμ-myc correlates with an increased number of small lymphocytes within the cords and sinuses, as well as some nodular aggregates surrounding a small vessel, indicative of spleen metastasis. The most significant metastasis was observed in the spleen of Eμ-myc;Mdm2 m/m ;p19Arf −/− compound mice. Similar to the spleen, lymphocyte infiltration in the liver can be seen in each of the Eμ-myc transgenic mice, specifically in the region surrounding the central veins. Not surprisingly, the most obvious liver metastasis was observed in Eμ-myc;Mdm2 m/m ; p19Arf −/− compound mice (Figure 3b ). Kidney metastasis usually occurs in advanced or late-stage lymphomas, and metastatic tumor cells were detected as diffuse and disorganized cells infiltrating between the glomerulus and tubules. 28 As shown in Figure 3b , in WT, Eμ-myc;WT, Eμ-myc;Mdm2 m/m and Eμ-myc; p19Arf −/− mice, kidneys revealed no discernible pathological To determine if cells in Eμ-myc-expressing spleens retained their proliferative capacity, Ki-67 staining was used to assess cellular proliferation by immunohistochemistry. As shown in Figure 3c , in the absence of the Eμ-myc transgene Ki-67 expression was barely detectable in the spleen of 9-week-old WT mice (Ki-67 index 0.4). In Eμ-myc;WT mice, we detected increased numbers of Ki-67positive cells (Ki-67 index 2.8); the number of Ki-67-positive cells was further increased in spleens from Eμ-myc;Mdm2 m/m and Eμmyc;p19Arf −/− mice (Ki-67 index 12.2 and 14.6, respectively). In spleens of Eμ-myc;Mdm2 m/m ;p19Arf −/− compound mice the number of Ki-67-positive cells was even further increased (Ki-67 index 53.9).
To examine apoptosis in the spleen tumors of the transgenic mice, TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling) immunohistochemical analysis was performed. Representative pictures of TUNEL-stained sections are shown in Figure 3d . Consistent with previous studies that Eμmyc induces apoptosis in transgenic spleens, 29 in spleens of 9week-old Eμ-myc;WT, Eμ-myc;Mdm2 m/m and Eμ-myc;p19Arf −/− mice, we detected high levels of TUNEL-positive apoptotic cells (14.6, 13.6, and 14.4%, respectively). However, in spleens of Eμmyc;Mdm2 m/m ;p19Arf −/− compound mice the number of TUNELpositive apoptotic cells decrease to 6.2%.
Local invasion and distant metastasis of lymphomas are commonly observed in Eμ-myc transgenic mice; we therefore analyzed liver tissues from individual mice for signs of metastasis. Eμ-myc transgenic mice were monitored for signs of moribund conditions, 30 and moribund mice were killed and the livers were collected and examined for sign of metastasis. Tumors were detected in the livers of Eμ-myc;WT transgenic mice at an average age of 22 weeks (Figure 3e ). In contrast, tumor onset in the liver was detected much earlier in Eμ-myc;Mdm2 m/m , Eμ-myc;p19Arf −/− and Eμ-myc;Mdm2 m/m ;p19Arf −/− mice, with progressively shorter time of onset at 13, 11 and 9 weeks, respectively ( Figure 3e ). These results demonstrate that individually the Mdm2 C305F mutation and p19Arf deletion promote local invasion and distant metastasis of Eμ-myc-induced lymphomas, with p19Arf deletion having a stronger effect than Mdm2 C305F mutation, which is consistent with the shorter lifespan of the Eμ-myc;p19Arf −/− mice compared to the Eμ-myc;Mdm2 m/m mice (Figure 2c ). Concurrent Mdm2 C305F mutation and p19Arf deletion further accelerates the aggressiveness of the lymphoma, resulting in an even shorter lifespan, consistent with the notion that the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 represent two non-redundant, independent pathways for tumor suppression. (Figure 4b ). Furthermore, the increased protein level of p53 was directly correlated with its transcriptional activity, indicated by S-18 phosphorylation of p53 in the spleens (p21 was undetectable in spleens; Figure 4a ), and increased p21 protein level in pBabe-c-Myc infected MEFs (Figure 4b) .
To corroborate the protein analysis, we carried out quantitative RT-PCR to further examine p53 activity in 4-week-old, nontumor-bearing Eμ-myc;WT, Eμ-myc;Mdm2 m/m , Eμ-myc;p19Arf −/− and Eμ-myc;Mdm2 m/m ;p19Arf −/− mouse spleens and in spleens from their non-transgenic counterparts. We chose p53 targets involved in cell cycle regulation (p21), apoptosis induction (Bax and Apaf1) and metabolism regulation (TIGAR) to determine whether p53 is activated universally for its target genes. Induction of each of these p53 target genes was evident in Eμ-myc;WT, Eμmyc;Mdm2 m/m and Eμ-myc;p19Arf −/− mouse spleens, but not in Eμmyc;Mdm2 m/m ;p19Arf −/− mouse spleens (Figures 4c and f) , consistent with protein analysis. Together, our data indicate that not only can the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 pathways be independently responsible for oncogenic c-Myc induction of p53, but also that the two pathways together contribute to most if not all p53 tumor suppressor response to c-Myc activation. Disabling both pathways results in undetectable p53 activation by oncogenic c-Myc overexpression.
DISCUSSION
The importance of p19Arf-Mdm2-p53 and RP-Mdm2-p53 signaling pathways in defending against oncogenic c-Mycinduced tumorigenesis is well established, and studies have shown that disruption of each of the two pathways by deletion or mutation accelerates the progression of malignancy in c-Mycexpressing mice. 13, 15 In this study, we generated and analyzed mice with concurrent disruption of these two pathways and compared p53 activity and tumorigenesis to mice with disruption of each pathway alone. The significance and implications of these findings are discussed below.
The p19Arf-Mdm2-p53 and the RP-Mdm2-p53 signaling pathways act independently in oncogenic c-MYC-induced p53 activation The generation of Mdm2 m/m mice has allowed for a detailed in vivo characterization of the role of RP-Mdm2 binding in p53 activation and tumor suppression. Unlike the disruption of the p19Arf-Mdm2-p53 pathway by p19Arf deletion, which results in spontaneous tumor development, 33 disruption of the RP-Mdm2-p53 pathway by Mdm2 C305F mutation does not result in spontaneous tumor development. 15 The different tumorigenic potential between the two mouse models could be a result of the nature of the two pathways in each of the mouse models. In the p19Arf −/− mice the entire p19Arf gene is deleted, disrupting p19Arf-Mdm2 binding as well as all other p19Arf-related functions; in the Mdm2 m/m mice, however, the single-point mutation in the Mdm2 is less disruptive, and while Mdm2 C305F mutant protein cannot properly bind to RPL5/RPL11, it retains binding to RPL23, 22 thus only reducing but not eliminating the functions of this pathway. Alternatively, it is conceivable that the p19Arf-Mdm2-p53 pathway primarily responds to deregulated oncogenes, which inflict a great risk of tumor formation if left unchecked, whereas the RP-Mdm2-p53 pathway may primarily respond to deregulated ribosome biosynthesis, which may play a lesser role in promoting cancerous growth.
In addition, it has been shown that p19Arf binds to and inhibits the ability of c-Myc to induce hyperproliferation and transformation through 34, 35 indicating loss of p19Arf could contribute to c-Myc-induced tumorigenesis by at least two mechanisms. Similarly, it has been shown that RPL11 binds to c-Myc and inhibits its transcriptional activity 36 and that RPL5, cooperatively with RPL11, guides the RNA-induced silencing complex to c-Myc mRNA and mediates the degradation of c-Myc mRNA. 37 These studies in combination with our results point to the importance of both p19Arf and RP signaling in c-Myc-induced lymphomagenesis. Our results agree with the notion that Eμ-myc-induced lymphomagenesis can be accelerated by disruption of negative regulators of c-Myc in each pathway in addition to disruption of p53 activation.
Our study also addresses the degree of cooperation between the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways in p53 response to oncogenic c-Myc overexpression. When Mdm2 C305F mutation or p19Arf deletion occur individually, c-Myc overexpression still elicits sufficient p53 response; however, when Mdm2 C305F mutation and p19Arf deletion occur concurrently, c-Myc overexpression does not elicit p53 activation. Given the role of oncogenic c-Myc in promoting aberrant ribosomal biogenesis, the p19Arf-independent, c-Myc-mediated induction of p53 in the p19Arf −/− cells is conceivably dependent on c-Myc-induced overexpression of RPs, which activate p53 through interaction with Mdm2. 15 Conversely, activation of p53 by c-Myc in Mdm2 m/m mice is p19Arf dependent, as the p19Arf-Mdm2-p53 pathway remains intact in mice and c-Myc can induce p19Arf expression ( Figure 4 ). Our data suggest that p53 responds to c-Myc overexpression via two independent signaling pathways: (Figure 5 ). Intriguingly, the lack of detectable p53 activation in the Eμ-myc; Mdm2 m/m ;p19Arf −/− compound mice implies that other active mechanisms transmitting oncogenic c-Myc signal to p53 either may not exist or be insufficient to raise p53 to a detectable level.
The p19Arf-Mdm2 connection mediates a p53-dependent checkpoint in response to a broad range of oncogenic insults, including elevated expression of c-Myc, E2F1, Ras, E1A and BCR-ABL. However, the RP-Mdm2 connection provides evidence for a prevailing in vivo checkpoint for the integrity of ribosome biogenesis to invoke p53 response if the process goes awry. Given that overexpression of many oncogenes promotes fast growth and proliferation, which inevitably requires accelerated ribosomal biogenesis it is reasonable to speculate that the RP-Mdm2-p53 signaling pathway, in addition to responding to c-Myc overexpression, may also respond to other deregulated oncogenes that cause superfluous ribosomal biogenesis. The Mdm2 m/m mouse model provides a convenient tool to investigate whether the RP-Mdm2-p53 pathway, as in the case of the p19Arf-Mdm2-p53 pathway, functions generally in oncogenic signaling surveillance, capable of responding to a broad range of deregulated oncogenes, or is only specific to oncogenic c-Myc.
MATERIALS AND METHODS

Ethics statement
Investigation has been conducted in agreement with the ethical standards according to the Declaration of Helsinki, national and international guidelines, and has been approved by the authors' institutional review board.
Cell culture
Primary MEFs were isolated on embryonic (E) day 13.5 and grown in a 37°C incubator with 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) supplied with 10% fetal bovine serum and penicillin-streptomycin. For retroviral infections, WT, Mdm2 m/m , p19Arf −/− and Mdm2 m/m ;p19Arf −/− MEFs were infected with retroviruses expressing c-MYC or pBabe control vector, and selected with puromycin (2.5 μg/ml) for 3 days. Infected MEFs were then allowed to recover for 48 h and harvested for analysis. MEFs at passage 4 were used for growth curves, western blotting and other analyses.
Mouse experiments
Mice were bred and maintained strictly under protocol (13-044) approved by the Institutional Animal Care and Use Committee in the University of North Carolina Animal Care Facility. Mdm2 m/m females were bred with p19Arf −/− males to obtain Mdm2 +/m ;p19Arf +/ − offspring, which were then crossed with Mdm2 +/m ;p19Arf +/ − mice to obtain Mdm2 m/m ;p19Arf −/− compound mice. For c-MYC-mediated tumorigenesis study, Mdm2 m/m ; p19Arf −/− females were bred with Eμ-myc transgenic males to obtain Eμ-myc;Mdm2 +/m ;p19Arf +/ − offspring, which were then crossed with Mdm2 +/m ;p19Arf +/ − mice to obtain Eμ-myc;Mdm2 m/m ;p19Arf −/− compound mice. Eμ-myc mice were purchased from Jackson Laboratory (002728). For survival studies, mice were palpated regularly for early signs of inguinal lymph node enlargement and monitored for tumor progression and signs of morbidity. Moribund mice were humanely euthanized. Mouse tumors and organs were fixed in formalin for histopathology and snap frozen for protein and RNA extraction.
Protein analysis
For western blot, MEFs were lysed with 0.5% (Tergitol, Sigma, St Louis, MO, USA) NP-40 lysis buffer. For mouse tissue protein extraction, tissue from the spleen, thymus and lymphomas was ground by mortar and pestle with liquid N 2 , and protein was extracted with 0.5% NP-40 lysis buffer. Mouse monoclonal anti-Mdm2 (2A10, Calbiochem, Billerica, MA, USA), p53 (NCL-505, Novocastra, Buffalo Grove, IL, USA), actin (MAB1501, Chemicon International, Billerica, MA, USA), goat polyclonal anti-p53 (FL-393, Santa Cruz Biotechnology, Dallas, TX, USA) and rat monoclonal anti-p19Arf (5-C3-1, Santa Cruz Biotechnology) antibodies were purchased commercially. Rabbit polyclonal antibodies to p21 were gifts from Dr Yue Xiong (UNC-Chapel Hill). Rabbit polyclonal antibodies to L5 and L11 were made in house as previously described. 22 Measurement of mouse tissue Spleens, kidneys and livers from 9-week-old mice were excised, photographed and weighed. All procedures involving mice were carried out according to protocol 13-044, approved by the University of North Carolina Institutional Animal Care and Use Committee.
Histopathology
Animals were autopsied and all tissues were examined regardless of their pathological status. Spleen, kidney and liver tissue from Eμ-myc;WT, Myc; Mdm2 m/m , Eμ-myc;p19Arf −/− and Eμ-myc;Mdm2 m/m ;p19Arf −/− transgenic mice, as well as tissue from non-transgenic counterparts were fixed overnight in 10% phosphate-buffered formalin and then transferred to 70% ethanol. Samples were sent to the UNC Histology Core Facility for paraffin embedding. Paraffin blocks were sectioned at 5-mm intervals for successive layers and stained with H&E for histopathology examination.
Proliferation analysis
Ki-67 immunohistochemical staining of mouse spleen samples was used to detect proliferating cells. Antigen retrieval for antibody on formalin-fixed paraffin sections was carried out by boiling paraffin samples in citrate buffer (pH 6.0) for 15 min. Endogenous peroxidase activity was quenched by incubation in 3% H 2 O 2 in methanol for 10 min. Antibody detection was carried out with purified mouse anti Ki-67 primary antibody (BD Pharmingen, San Diego, CA, USA) and biotin-conjugated anti-mouse secondary antibody (Vector Laboratories, Burlingame, CA, USA). Ki-67expressed cells were stained brown color by biotin-peroxidase kit (VECTASTAIN Elite, Vector Laboratories). The ratio of positively stained cells to total cells was calculated. Student's t-test (Po0.05 was considered significant) was used to compare the differences in proliferation levels between the different mouse genotypes.
Apoptosis analysis
Levels of apoptosis in mouse spleen sections were assessed by the TUNEL assay according to instructions (ApopTag Peroxidase in situ kit, S7100, Millipore, Temecula, CA, USA).
Quantitative real-time PCR
Total RNA was isolated using an RNeasy kit (74104, Qiagen, Hilden, Germany) and cDNA was synthesized using SuperScript III (18080400, Life Technologies, Waltham, MA, USA). qRT-PCR was performed with SYBR green master mix using the 7900HT fast real-time PCR system (Applied Biosystems, Waltham, MA, USA) according to manufacturers' instructions. Data were collected and exported with SDS 2.2.2 software (Applied Biosystems). Relative expression was calculated using actin as an internal control as indicated. Primers used were as follows: p21, 5′-CC TGGTGATGTCCGACCTG-3′ and 5′-CCATGAGCGCATCGCAATC-3′; Bax, 5′-GG ACAGCAATATGGAGCTGCAGAGG-3′ and 5′-GGAGGAAGTCCAGTGTCCAGCC -3′; Apaf1, 5′-CGGTGAAGGTGTGGAATGTCATTACCG-3′ and 5′-GGATTTCTC CATTGTCATCTCCAGTTGC-3′; TIGAR, 5′-CGATCTCACGAGGACTAAGCAGAC C-3′ and 5′-GCCAAAGAGCTTTCCAAACCGCTGC-3′; and Actin, 5′-CCACAG CTGAGAGGGAAATCGTGC-3′ and 5′CCAGAGCAGTAATCTCCTTCTGCATC C-3′.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism 5 Software (Graph-Pad Software, San Diego, CA, USA). Kaplan-Meier survival curve was carried out to assess lifespan.
